HCR.20.049 – The PELICAN Consortium: Joint forces for personalized lifestyle support to improve response and reduce side-effects of cancer treatment.
One out of three individuals is diagnosed with cancer. Survival rates of most common cancers are high. However, complications and side-effects of surgery, chemo- and radiotherapy may have substantial negative impact on prognosis as well as on physical and mental health impairing quality of life and societal participation.
An individual’s response to cancer therapy and its side-effects may depend on tumour and personal characteristics as well as lifestyle factors. Personalised approaches to optimise outcomes of cancer treatment are limited as long as the underlying mechanisms explaining an individual’s response to cancer therapy are unknown. To be able to optimise treatment for each individual patient, differences in tumour characteristics, treatment, personal characteristics and lifestyle, but also in personal needs, and preferences, should be taken into account. Digital tools may offer a promising means to implement personalised approaches, aimed at promotion of sustained health behaviour change, in clinical care.
The PELICAN consortium will join forces to build a research infrastructure including ongoing prospective cancer cohort studies with data on treatment and outcomes. These existing cohort studies are collecting bio-specimens and data on quality of life and lifestyle factors, such as diet, dietary supplements and body composition at several time points before, during and after treatment. Combining data will provide the statistical power to identify personal/clinical characteristics and lifestyle factors associated with side-effects, co-morbidities, cancer recurrence and mortality. This efficient infrastructure will also serve as a sampling frame to allow sub-studies to evaluate 1) biological mechanisms and 2) state-of-the art, smart applications (such as side-effects apps, sensors of response, and 3) personal lifestyle interventions.
Results will be translated to personalised lifestyle support implementable in clinics. Throughout this initiative, tools will be developed and evaluated in collaboration with patients and healthcare providers, to promote uptake, compliance and effectiveness.
cancer treatment, individual response, lifestyle, personalized support, side-effects
Alliance Nutrition & Health Care, Nederlandse Federatie Van Patientenorganisaties, Netherlands Comprehensive Cancer Organisation (IKNL), Radboud Medical Center (RUMC), Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Tilburg University (TiU), UMC Utrecht (UMCU), University Maastricht (UM), Werkgroep Dietisten Oncologie (LWDO), World Cancer Research Fund-NL, WUR-FBR
|Organisation||Wageningen University (WUR)|
|Name||Prof. dr. E. (Ellen) Kampman|